CareDx Launches AlloSeq Nano for Faster HLA Typing Amid Lab Business Sale
Event summary
- CareDx introduced AlloSeq Nano, a nanopore-based HLA and ABO genotyping solution, at EFI 2026 on April 20, 2026.
- AlloSeq Nano delivers high-resolution HLA genotyping in under three hours with 45 minutes of hands-on time.
- CareDx agreed to sell its Lab Products business to EuroBio Scientific, expected to close by Q3 2026.
- The company will host a satellite symposium at EFI 2026 on April 23 to discuss AlloSeq Nano and its transplant diagnostics portfolio.
The big picture
CareDx's launch of AlloSeq Nano underscores its commitment to advancing transplant diagnostics, even as it prepares to divest its Lab Products business. The move reflects broader industry trends toward faster, more accurate genotyping solutions, which are critical for improving transplant outcomes. The divestiture suggests a strategic pivot, potentially allowing CareDx to focus more on its core molecular testing and digital health technologies.
What we're watching
- Integration Challenges
- Whether CareDx can smoothly transition its Lab Products business to EuroBio Scientific while maintaining product momentum.
- Market Adoption
- The pace at which AlloSeq Nano gains traction in the HLA typing market, particularly against existing solutions.
- Strategic Focus
- How CareDx will allocate resources post-divestiture to drive growth in its remaining business segments.
Related topics